Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

features: Neuromuscular Disorders

First ever targeted treatment for SOD1-ALS: FDA approve tofersen

On April 25th, 2023, the U.S. Food and Drug Administration (FDA) approved tofersen (BIIB067) for the treatment of amyotrophic lateral…

Newborn screening improves health outcomes in infants with spinal muscular atrophy

Spinal muscular atrophy (SMA) is a severe genetic disease associated with mutations in the SMN1 gene (SMA5q). The pathological characteristics…

Top clinical trial updates from AAN 2021: MG, PD & ALS

Discover updates from major clinical trials in myasthenia gravis, Parkinson’s disease & ALS presented at AAN 2021!